The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial
Open accessAbstract
IMPORTANCE: Deficient mismatch mutation repair mechanisms may sensitize endometrial cancers to anti-programmed death 1 (PD-1) therapies. Dostarlimab (TSR-042) is an investigational anti-PD-1 antibody that binds with high affinity to the PD-1 receptor. OBJECTIVE: To assess the antitumor activity and safety of dostarlimab for patients with deficient mismatch repair endometrial cancer. DESIGN, SETTING, AND PARTICIPANTS: This ongoing, open-label, single-group, multicenter study began part 1 on March 7, 2016, and began enrolling patients with deficient mismatch mutation repair endometrial cancer on May 8, 2017. Median follow-up was 11.2 months (range, 0.03 [ongoing] to 22.11 [ongoing] months; based on radiological assessments). Statistical analysis was performed July 8 to August 9, 2019. INTERVENTIONS: Patients received 500 mg of dostarlimab intravenously every 3 weeks for 4 doses, then 1000 mg every 6 weeks until disease progression, treatment discontinuation, or withdrawal. MAIN OUTCOMES AND MEASURES: The primary end point was objective response rate and duration of response by blinded independent central review using Response Evaluation Criteria in Solid Tumors, version 1.1. RESULTS: As of the data cutoff, 104 women (median age, 64.0 years [range, 38-80 years]) with deficient mismatch mutation repair endometrial cancers were enrolled and treated with dostarlimab. Of these, 71 had measurable disease at baseline and at 6 months or more of follow-up and were included in the analysis. There was a confirmed response in 30 patients (objective response rate, 42.3%; 95% CI, 30.6%-54.6%); 9 patients (12.7%) had a confirmed complete response, and 21 patients (29.6%) had a confirmed partial response. Responses were durable; the median duration of response was not reached (median follow-up was 11.2 months). The estimated likelihood of maintaining a response was 96.4% at 6 months and 76.8% at 12 months. Anemia (3 of 104 [2.9%]), colitis (2 of 104 [1.9%]), and diarrhea (2 of 104 [1.9%]) were the most common grade 3 or higher treatment-related adverse events. CONCLUSIONS AND RELEVANCE: In this nonrandomized trial, dostarlimab was associated with clinically meaningful and durable antitumor activity with an acceptable safety profile for patients with deficient mismatch mutation repair endometrial cancers after prior platinum-based chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02715284.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048
Aghajanian, C., Sill, M. W., Darcy, K. M., Greer, B., McMeekin, D. S., Rose, P. G., Rotmensch, J., Barnes, M. N., Hanjani, P., & Leslie, K. K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.6397 · Cited by 326
O’Neil, B. H., Wallmark, J. M., Lorente, D., Elez, E., Raimbourg, J., Gomez-Roca, C., Ejadi, S., Piha-Paul, S. A., Stein, M. N., Abdul Razak, A. R., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0189848 · Cited by 296
Konstantinopoulos, P. A., Luo, W., Liu, J. F., Gulhan, D. C., Krasner, C., Ishizuka, J. J., Gockley, A. A., Buss, M., Growdon, W. B., Crowe, H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01021 · Cited by 224
Lincoln, S., Blessing, J. A., Lee, R. B., & Rocereto, T. F. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(02)00068-9 · Cited by 175
Cited by
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Ajani, J. A., D’Amico, T. A., Bentrem, D. J., Chao, J., Cooke, D., Corvera, C., Das, P., Enzinger, P. C., Enzler, T., Fanta, P., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0008 · Cited by 1,684
Crosbie, E. J., Kitson, S. J., McAlpine, J. N., Mukhopadhyay, A., Powell, M. E., & Singh, N. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00323-3 · Cited by 1,333
Huang, R., & Zhou, P.-K. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00648-7 · Cited by 907
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Mirza, M. R., Chase, D. M., Slomovitz, B. M., dePont Christensen, R., Novák, Z., Black, D., Gilbert, L., Sharma, S., Valabrega, G., Landrum, L. M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2216334 · Cited by 862
Self-citationPembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Eskander, R. N., Sill, M. W., Beffa, L., Moore, R. G., Hope, J. M., Musa, F. B., Mannel, R., Shahin, M. S., Cantuaria, G. H., Girda, E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302312 · Cited by 758
Self-citation
Metadata
- Authors
- Oaknin, A., Tinker, A. V., Gilbert, L., Samouëlian, V., Mathews, C., Brown, J., Barretina-Ginesta, M.-P., Moreno, V., Gravina, A., Abdeddaim, C., Banerjee, S., Guo, W., Danaee, H., Im, E., & Sabatier, R.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2020-11-01
- Volume
- 6
- Issue
- 11
- Pages
- 1766
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W3090741377
- Cited by
- 364
- References
- 17
- FWCI
- 18.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaoncol.2020.4515
- The paper
- Oaknin, A., Tinker, A. V., Gilbert, L., Samouëlian, V., Mathews, C., Brown, J., Barretina-Ginesta, M.-P., Moreno, V., Gravina, A., Abdeddaim, C., Banerjee, S., Guo, W., Danaee, H., Im, E., & Sabatier, R. (2020). Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2020.4515
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.